Rays Power Infra announced closure of INR 127 Crore Equity Capital Fund Raise - Rentomojo Limited Announced it's Initial Public Offer (IPO) to open on Wednesday, September 09, 2026 Price Band has been fixed at ₹ 384 to ₹ 404 per Equity Share - Manipal Payment and Identity Solutions Limited Announced its Initial Public Offering (IPO) to Open on Wednesday, September 9, 2026 Price Band fixed at ₹322 to ₹339 per equity share of face value of ₹10 each - LCC Projects fixes IPO price band at Rs 139-146 per share; issue opens on Sep 9 - KARAMTARA ENGINEERING LIMITED ANNOUNCED ITS INITIAL PUBLIC OFFERING (IPO) OF EQUITY SHARES TO OPEN ON WEDNESDAY 09 SEPTEMBER 2026 Price Band fixed at ₹241 to ₹254 per equity share of face value of ₹10 each - LCC Projects Limited announces the price band for its IPO - Ola Electric's First Dealer Stores are Now Open across India - Prasol Chemicals Limited Announced its initial Public Offering (IPO) to Open on September 8 at Price Band of ₹643–₹676 - Asset Reconstruction Company (India) Limited Announced it's Initial Public Offering (IPO) to open on Wednesday, September 09, 2026 The Price Band of the Offer has been fixed from ₹ 132 per Equity Share of face value ₹ 10 each to ₹139per Equity Share of face value of ₹ 10 each - Veegaland Developers Limited’s IPO to Open on Thursday, September 10, 2026 Price Band fixed at ₹130 to ₹140 per equity share of face value of ₹10 each - Veegaland Developers Limited’s IPO to Open on Thursday, September 10, 2026 At the Price Band fixed at ₹130 to ₹140 per equity share of face value of ₹10 each

January 2024

No Picture

Fonebox Retail IPO opens on Wednesday, January 24, 2024; price band fixed at Rs. 66 – Rs. 70 per share

·       The offer will open on Wednesday, January 24, 2024, and close on Monday, January 29, 2024; Anchor book will open on Tuesday, January 23,2024 ·       IPO comprises of fresh issue of 29,10,000 Equity Shares with a…




No Picture

Winner and Finalist of the Social Entrepreneur of the Year (SEOY) Award – India platform, Won the prestigious ‘Social Innovators of the Year 2024’ Award by The Schwab Foundation for Social Entrepreneurship at the World Economic Forum’s Annual Meeting 2024 at Davos, Switzerland

Hilde Schwab, Chairperson and Co-Founder, Schwab Foundation for Social Entrepreneurship, Rudayna Abdo, Founder and Chief Executive Officer, Thaki, Lebanon, Gerald Abila, Founder and Chief Executive Officer, BarefootLaw, Uganda, Shuchin Bajaj, Founder and Director, Ujala Cygnus…


No Picture

Google’s Gemini Pro and Imagen 2 to deploy in producing new text, voice, and image features on the new Samsung Galaxy S24 series

  US, January 17, 2024 (GNI): Samsung Electronics Co., Ltd. and Google Cloud today announced a new multi-year partnership to bring Google Cloud’s generative artificial intelligence (AI) technology to Samsung smartphone users around the globe. Starting…


Samsung Ushers in Mobile AI Era, Launched Galaxy S24 Series in India; Pre-book Now for Exciting Offers

JB Park President & CEO, Samsung Southwest Asia Samsung Ushers in Mobile AI Era, Launches Galaxy S24 Series in India; Pre-book Now for Exciting Offers ·       Customers pre-booking Galaxy S24 Ultra & Galaxy S24+ will get…


NSE is the world’s largest derivative exchange for fifth consecutive Year Ranks 3rd largest globally in equity segment in calendar year 2023

NSE is the world’s largest derivative exchange for fifth consecutive Year Ranks 3rd largest globally in equity segment in calendar year 2023 Mumbai, 18th January 2024 (GNI): NSE Group (National Stock Exchange of India and…



No Picture

CAR Tcell यास्वदेशी थेरपीने कोकिलाबेन धीरूभाई अंबानी हॉस्पिटल मुंबईमध्ये ब्लड कॅन्सरउपचारांमध्ये नवी क्षितिजे खुली केली

मुंबई, 18 जानेवारी 2024 (GNI):  CAR T cell कायमेरिक  अँटीजेन रिसेप्टर T-cell थेरपी इम्युनोथेरपीचा  नवीन,  आशादायक प्रकार आहे.  ज्यामध्ये केमोथेरपी किंवा इतर उपचारांचा काहीही उपयोग होत नाही अशा काही पुढच्या टप्प्यात पोहोचलेल्या ब्लड कँसरमध्ये ही थेरपी उपयोगी ठरते. आता ही थेरपी कोकिलाबेन धीरूभाई अंबानी हॉस्पिटल मुंबईमध्ये उपलब्ध आहे. ही थेरपी प्रत्येक रुग्णानुसार विकसित केली जाते आणि कँसरला टार्गेट करण्यासाठी रुग्णाच्या स्वतःच्या इम्यून सिस्टिम सेल्सना रिप्रोग्रामिंग करून काम करते. या इम्यून सेल्सना टी सेल्स किंवा टी लिम्फोसाईट्स म्हटले जाते, या पेशी संसर्गापासून आपले रक्षण करतात आणि कर्करोगाच्या पेशींना नष्ट करण्यात महत्त्वपूर्ण भूमिका बजावतात. अगदी हल्लीपर्यंत ही थेरपी फक्त युनायटेड स्टेट्स, काही युरोपियन देश, इस्त्रायल व चीनमध्ये उपलब्ध होती. पण नुकतेच केंद्रीय औषधे नियंत्रण मानक संस्थेने (CDSCO) भारतातील पहिल्या स्वदेशात विकसित करण्यात आलेल्या CAR-T cell  उत्पादनाला मार्केट ऑथोरायजेशन दिले आहे. स्वदेशात विकसित करण्यात आलेली कायमेरिक अँटीजेन रिसेप्टर (CAR) T-cell थेरपी भारतातील पुन्हा-पुन्हा होणाऱ्या बी-सेल लिम्फोमा  किंवा ल्युकेमियाच्या रुग्णांना नवी आशा प्रदान करते. खासकरून ज्यांच्या पारंपरिक थेरपीज करून संपल्या आहेत अशा रुग्णांसाठी हा खूप मोठा दिलासा आहे. कोकिलाबेन धीरूभाई अंबानी हॉस्पिटल मुंबईचे सिनियर कन्सल्टन्ट – हेमेटो ऑन्कोलॉजी आणि बोन मॅरो ट्रान्सप्लान्टेशन डॉ समीर ए तुळपुळे यांनी सांगितले, “ CAR T-cell थेरपी वैयक्तिक दृष्टिकोनातून कॅन्सर उपचारांचा एक प्रकार आहे. भारतात अनेक रुग्णांना या ब्लड कॅन्सरच्या या अत्याधुनिक उपचाराचे लाभ मिळतील, याचा भारतातील खर्च परदेशात येणाऱ्या खर्चाच्या फक्त एक-दशांश इतका आहे.  हा अत्याधुनिक उपचार ब्लड कॅन्सरच्या रुग्णांसाठी विशेष तयार करण्यात आलेल्या कॅन्सर देखभालीमध्ये महत्त्वपूर्ण प्रगतीचे एक प्रतीक आहे.” त्यांनी पुढे सांगितले, “यामध्ये अनेक टप्पे असतात.  ही थेरपी एफेरेसिस प्रक्रियेमार्फत केली जाते, यामध्ये रुग्णाचे रक्त एका मशिनमार्फत वाहते, जे T cells ना वेगळे करते. या T cells ना कॅन्सरला मारणाऱ्या सुपरचार्ज्ड सेल्स बनवण्यासाठी CAR जोडून प्रयोगशाळेमध्ये जेनेटिक मॉडिफिकेशन केले जाते. त्यानंतर त्यांची संख्या वाढू दिली जाते. पुरेशा पेशी तयार होईपर्यंत काही दिवसांसाठी रुग्णाला सुरुवातीचे उपचार दिले जातात. त्यानंतर पेशी पुन्हा रुग्णाच्या शरीरात सोडल्या जातात. हे उपचार केल्यावर काही प्रतिकूल परिणाम होऊ नयेत यासाठी रुग्णाची १० ते १२ दिवस देखभाल केली जाते. हॉस्पिटलमधून घरी पाठवण्यात आल्यानंतर रुग्णाचे बारकाईने फॉलो-अप केले जाते  आणि केमोथेरपी करतेवेळी जी काळजी घेतली होती, त्याचप्रमाणे स्टॅंडर्ड काळजी घेणे आवश्यक असते.”ends GNI


No Picture

Highest ever quarterly PAT of ₹265 crore in Q3 FY24, jumps 76% YoY, AUM up 58% YoY to ₹21,946 crore: NNPA down to 0.70% Declares 100% Interim Dividend 

Pune, January 18, 2024 (GNI): The Board of Directors of Poonawalla Fincorp Limited, a non-deposit taking systemically important NBFC, focusing on consumer and MSME finance, today announced its unaudited financial results for the quarter ended December…